Targeting TLR2/Rac1/cdc42/JNK Pathway to Reveal That Ruxolitinib Promotes Thrombocytopoiesis

Background: Thrombocytopenia has long been considered an important complication of chemotherapy and radiotherapy, which severely limits the effectiveness of cancer treatment and the overall survival of patients. However, clinical treatment options are extremely limited so far. Ruxolitinib is a poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shuo, Tang, Xiaoqin, Wang, Long, Ni, Chengyang, Wu, Yuesong, Zhou, Ling, Zeng, Yueying, Zhao, Chunling, Wu, Anguo, Wang, Qiaozhi, Xu, Xiyan, Wang, Yiwei, Chen, Rong, Zhang, Xiao, Zou, Lile, Huang, Xinwu, Wu, Jianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787584/
https://www.ncbi.nlm.nih.gov/pubmed/36555781
http://dx.doi.org/10.3390/ijms232416137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787584/
https://www.ncbi.nlm.nih.gov/pubmed/36555781
http://dx.doi.org/10.3390/ijms232416137

Ejemplares similares